Differential cytoprotection by glycine against oxidant damage to proximal tubule cells.
Tert-butyl hydroperoxide (tBHP) injured freshly isolated proximal tubules in an Fe-dependent fashion that was ameliorated by a lipophilic antioxidant, diphenyl-p-phenylenediamine (DPPD), but was only minimally affected by glycine. Menadione-induced injury was Fe-independent and was unaffected by DPPD, but was strongly blocked by glycine. Fe was highly toxic when intracellular loading was facilitated by concomitant treatment with hydroxyquinoline (HQ). This toxicity was blocked by DPPD or chelating the Fe, but not by glycine. All of the lesions were characterized by severe depletion of glutathione and other soluble thiols. Menadione induced large increases in protein associated with the Triton-insoluble cytoskeleton and decreases in protein thiol content, consistent with extensive cross linking, but did not increase thiobarbituric acid reactive substances (TBARS). tBHP and HQ + Fe had either no effect or only moderate, delayed effects on cytoskeletal proteins, but induced substantial increases of TBARS. Glycine did not the alter changes in cytoskeletal proteins, thiols, or TBARS produced by any of the agents. Protection against tBHP toxicity by deferoxamine and DPPD was accompanied by substantial suppression of TBARS accumulation. Superimposition of hypoxia during tBHP exposure reduced TBARS accumulation and restored cytoprotective activity to glycine. Thus, in contrast to its consistently strong cytoprotection against a number of other insults, glycine is only variably cytoprotective against oxidant lesions in freshly isolated proximal tubules. Extensive oxidative crosslinking of proteins is compatible with maintenance of glycine cytoprotection against lethal membrane damage. Fe-induced injury to proximal tubules associated with lipid peroxidation as manifested by TBARS formation is a relatively glycine-insensitive insult.
Sogabe
K
K
Department of Internal Medicine, University of Michigan, Ann Arbor, USA.
Roeser
N F
NF
Venkatachalam
M A
MA
Weinberg
J M
JM
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D015687:Cell Hypoxia / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D003676:Deferoxamine / Q000494:pharmacology; D005260:Female; D005998:Glycine / Q000494:pharmacology*; D006490:Hemostatics / Q000494:pharmacology; D006912:Hydroxyquinolines / Q000633:toxicity; D007501:Iron / Q000633:toxicity; D007687:Kidney Tubules, Proximal / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D010545:Peroxides / Q000633:toxicity; D010655:Phenylenediamines / Q000494:pharmacology; D011817:Rabbits; D017382:Reactive Oxygen Species; D017262:Siderophores / Q000494:pharmacology; D014812:Vitamin K / Q000633:toxicity; D020122:tert-Butylhydroperoxide
D000975:Antioxidants; D006490:Hemostatics; D006912:Hydroxyquinolines; D010545:Peroxides; D010655:Phenylenediamines; D017382:Reactive Oxygen Species; D017262:Siderophores; D014812:Vitamin K; D020122:tert-Butylhydroperoxide; C004845:N,N'-diphenyl-4-phenylenediamine; D007501:Iron; D003676:Deferoxamine; D005998:Glycine